EPIGENOMICS AG (ECX.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:ECX - DE000A37FT41 - Common Stock
ECX.DE Key Statistics, Chart & Performance
The current stock price of ECX.DE is 0.7 EUR. In the past month the price decreased by -57.32%. In the past year, price increased by 52.84%.
ECX.DE Technical Analysis
ECX.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ECX.DE. ECX.DE has a bad profitability rating. Also its financial health evaluation is rather negative.
ECX.DE Financial Highlights
Over the last trailing twelve months ECX.DE reported a non-GAAP Earnings per Share(EPS) of -17.68. The EPS decreased by -7359.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -386.29% | ||
| ROE | -853.33% | ||
| Debt/Equity | 0.06 |
ECX.DE Forecast & Estimates
6 analysts have analysed ECX.DE and the average price target is 16.32 EUR. This implies a price increase of 2231.43% is expected in the next year compared to the current price of 0.7.
For the next year, analysts expect an EPS growth of 47.75% and a revenue growth 2136.83% for ECX.DE
ECX.DE Ownership
About ECX.DE
Company Profile
Epigenomics AG is a DE-based company operating in Biotechnology industry. The company is headquartered in Berlin, Berlin and currently employs 18 full-time employees. The company went IPO on 2004-07-19. Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. The company develops and commercializes blood-based diagnostic products across multiple cancer indications. The firm's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. The company also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The firm is present in Europe and the United States.
Company Info
EPIGENOMICS AG
Geneststrasse 5
Berlin BERLIN DE
Employees: 18
Phone: 4930243450
EPIGENOMICS AG / ECX.DE FAQ
What does EPIGENOMICS AG do?
Epigenomics AG is a DE-based company operating in Biotechnology industry. The company is headquartered in Berlin, Berlin and currently employs 18 full-time employees. The company went IPO on 2004-07-19. Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. The company develops and commercializes blood-based diagnostic products across multiple cancer indications. The firm's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. The company also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The firm is present in Europe and the United States.
What is the current price of ECX stock?
The current stock price of ECX.DE is 0.7 EUR. The price decreased by -11.17% in the last trading session.
What is the dividend status of EPIGENOMICS AG?
ECX.DE does not pay a dividend.
What is the ChartMill rating of EPIGENOMICS AG stock?
ECX.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is EPIGENOMICS AG (ECX.DE) stock traded?
ECX.DE stock is listed on the Frankfurt Stock Exchange exchange.
Can you provide the PE ratio for ECX stock?
EPIGENOMICS AG (ECX.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-17.68).